FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:773-774 March 8, 2001 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: We concur with Krause et al. (Nov. 16 issue)¹ that the combination of azithromycin and atovaquone is effective for the treatment of babesiosis. We have been using atovaquone and azithromycin as an alternative treatment for babesiosis since 1993. Our studies of babesiosis in hamsters showed that atovaquone and azithromycin are effective agents for the treatment of babesiosis.^2,3

We have used a combination of azithromycin at a dose of 12 mg per kilogram of body weight per day and atovaquone at a dose of 40 mg per kilogram per day in neonates with success and without toxic effects.⁴ . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Stowell, C. P., Gelfand, J. A., Shepard, J.-A. O., Kratz, A. (2007). Case 17-2007 -- A 25-Year-Old Woman with Relapsing Fevers and Recent Onset of Dyspnea. NEJM 356: 2313-2319 [Full Text]  
• Takata, T. S., Page, R. L., Joglar, J. A. (2001). Automated External Defibrillators: Technical Considerations and Clinical Promise. ANN INTERN MED 135: 990-998 [Abstract] [Full Text]